Maximizing the Therapeutic Potential of HSP90 Inhibitors
about
Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70.In Vivo Conformational Dynamics of Hsp90 and Its Interactors.Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.Hsp90 activator Aha1 drives production of pathological tau aggregates.TRAP1: a viable therapeutic target for future cancer treatments?Tumour-associated antigens and their anti-cancer applications.HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells.Fused imidazoles as potential chemical scaffolds for inhibition of heat shock protein 70 and induction of apoptosis. Synthesis and biological evaluation of phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthrolines.Regulation of pulmonary endothelial barrier function by kinases.Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A.Regulation of Ubiquitin-like with Plant Homeodomain and RING Finger Domain 1 (UHRF1) Protein Stability by Heat Shock Protein 90 Chaperone Machinery.Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System.The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy.Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.Evidence for Hsp90 Co-chaperones in Regulating Hsp90 Function and Promoting Client Protein Folding.Computational Modeling of the Hsp90 Interactions with Cochaperones and Small-Molecule Inhibitors.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.HSP90 inhibition in angiosarcoma.Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.Adapting to stress - chaperome networks in cancer.Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum
P2860
Q27704725-2872F062-6F47-428D-A798-7C2B6FAD49C0Q37233917-4F14DB1F-0FF5-44EA-B66D-1D0497C62CBFQ37702589-990A06F1-BE57-4D92-B2EA-C49DA2DCB31BQ38615498-74377472-AC2E-4948-AC61-6AA495138BDDQ38664647-04E6F30B-D81D-438B-8A17-0EAC37391603Q38725552-4C5E7266-E22F-4C17-B4BE-7F89C3477EE1Q38732060-79FD312A-CFE6-4522-9AE7-26F1DC9DD793Q38737681-CCB1E62B-BD4C-42B5-AE33-D3F8788E48F5Q38747870-76F65292-A88F-4E96-8C7E-BC238BCC082CQ38781889-E0684DA2-7813-4857-8615-9F3318E317FAQ38963349-DC5954B5-4027-4200-9506-83DE1A8DDC95Q39120175-910C911C-317E-48CB-8185-3F649E07D70EQ41106970-04FE14C8-47A4-47FF-AC8F-48E8F3C61B06Q41127921-FC425E36-3B7D-489C-B66F-39EC192F1768Q41773399-AFF35CF0-9037-43C1-AD70-D32B296A693EQ45737789-D46E7235-874A-41B8-AAAA-5E12AEC85C0EQ45873271-D0832117-D916-425A-B84C-B35FCFC75D66Q47100164-03183DA9-FAB9-46D1-BA8B-9010042E4301Q47362455-A31889F1-103E-42B1-9647-399F5937AF09Q47362549-43F58A16-C5D0-48DD-8378-95863DAA1758Q47393972-93BC0F37-F795-4743-A800-3CC62953AC2BQ47429093-D3DB9FA8-8389-4CDB-8FED-8772EA84BB50Q47917132-2A017998-B634-42CA-B867-96A7FC9AE2E0Q48121004-3A0E1361-9383-4C38-B26C-A3D4D93EFCAEQ48210380-D7056014-C4A6-4D4E-8FC4-053789F88DFBQ49415335-48E7C82B-9E27-48E7-9AF0-E6AB124B5E47Q50942181-58B7A917-9B9F-40A1-8D85-9C068EEAC474Q54425017-E1A28E0D-A866-43B3-8667-365911F101E3Q56355675-67167155-38FA-4722-AAD2-6EE2ACC0C206
P2860
Maximizing the Therapeutic Potential of HSP90 Inhibitors
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@ast
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@en
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@en-gb
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@nl
type
label
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@ast
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@en
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@en-gb
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@nl
prefLabel
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@ast
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@en
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@en-gb
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@nl
P2860
P50
P1476
Maximizing the Therapeutic Potential of HSP90 Inhibitors
@en
P2093
Heather K Armstrong
Roberta Ferraldeschi
P2860
P304
P356
10.1158/1541-7786.MCR-15-0234
P407
P577
2015-11-01T00:00:00Z